GLP-1 weight loss marketing at a med spa is governed less by what you say about weight than by what you say about the drug: whether a compounded product is described as approved, as generic, or as the same thing as Ozempic or Zepbound. The FDA has now written that list down.
Every rule, date and enforcement action below is as of September 2026 and comes from the document named beside it. Educational marketing guidance, not legal or medical advice.
What the resolved shortages changed
The shortage route to compounding is closed. FDA determined the tirzepatide injection shortage resolved in December 2024 and the semaglutide injection shortage resolved in February 2025, and the enforcement discretion that let pharmacies and outsourcing facilities compound copies while those drugs sat on the shortage list has ended.
In April 2026 FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, saying it did not identify sufficient evidence of clinical need for outsourcing facilities to compound them from bulk substances. Comments closed on June 29, 2026, and no final determination had been announced as of September 2026.
None of that settles whether a particular prescription is lawful. That question belongs to your pharmacy and your medical director. It settles something narrower and more useful for marketing: a treatment page written in 2024, when compounded semaglutide was a shortage-era offer, is describing a legal situation that no longer exists.
The three claims FDA names
FDA has published a short list of claims it treats as false or misleading when a compounded GLP-1 is promoted: branding that implies the seller is the compounder, describing the compounded drug as a generic version of an FDA-approved drug or as the same as one, and claiming the drug is sourced from an FDA-approved or FDA-licensed pharmacy or outsourcing facility.
The list is worth reading as copy instructions rather than as legal theory, because that is the form the enforcement takes. The agency's underlying point is that FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed, so any sentence implying an approval is describing something that never happened.
| What FDA names as false or misleading | How it shows up in med spa copy | What the page can say instead |
|---|---|---|
| Branding implying the seller is the compounder | "Compounded in our own pharmacy" on a practice that orders from a third party | Name the licensed pharmacy that compounds it, or say nothing about who does |
| Calling it a generic version of an approved drug | "Generic Ozempic" or "generic Wegovy" in a headline, ad or price table | "Compounded semaglutide", with no comparison to the brand |
| Calling it the same as an FDA-approved drug | "Same active ingredient as Zepbound, a fraction of the cost" | State what it is: a compounded preparation FDA has not reviewed |
| Claiming an FDA-approved or FDA-licensed source | "From an FDA-approved compounding pharmacy" | Registered or state-licensed, where that is true; FDA approves drugs, not pharmacies |
The enforcement has been steady rather than symbolic. FDA issued warning letters over compounded GLP-1 website claims on September 9, 2025, announced a second set of 30 letters to telehealth companies on March 3, 2026, and was still sending them in June 2026. Those letters read websites. The claim is what draws one, which is why a med spa's own weight-loss page sits in the same category as a telehealth landing page.
The number in the ad belongs to the trial, not the vial
A weight-loss percentage lifted from a manufacturer's clinical trial is a claim about the drug that was studied, not about the compounded preparation on your shelf. The FTC's health products guidance says advertisers must have adequate substantiation "for all objective product claims conveyed, expressly or by implication", and that health benefits generally require randomized, controlled human clinical testing.
Patient stories do not fill that gap. The same guidance states that testimonials are not substantiation, and that "attempts to disclaim dramatic results with statements like 'Results not typical' don't cure the deception". Its own worked example is a weight-loss ad using a before-and-after photograph with a fine-print disclaimer, which the FTC calls inadequate.
What is left is a narrower lane that still sells. Describe the program rather than the outcome: the medical screening, who prescribes, the visit cadence, the monitoring, what happens if a patient stops. Let the trial numbers stay with the approved drug they were measured on and with whoever published them.
Where the ad platforms draw their own line
Meta's advertising standards require an advertiser promoting prescription drugs to be certified with LegitScript or cleared through Meta's internal review, with Meta authorization, targeting limited to people 18 and over, and only in eligible countries. Meta names online pharmacies, telehealth providers and pharmaceutical manufacturers, and does not mention med spas at all.
So whether a practice naming a prescription injectable is treated as a prescription-drug advertiser is an application question, not a settled one, as of September 2026. Meta does say separately that no written authorization is needed to run ads that educate or advocate about prescription drugs, or that promote telehealth services generally.
That points at the same campaign the FDA list points at. An ad that sells a medically supervised weight-loss consultation, and names the molecule nowhere, is both the version least likely to stall in review and the version with no room for the four sentences in the table above.
What does a GLP-1 program look like when the system runs it?
Practices selling a weight-loss program ask for HIPAA compliance across digital forms, CRM automations and ad landing pages, and GLP-1 is where that request gets literal: the landing page names the condition being treated, so it is the one page whose third-party tracking would hand an advertiser a diagnosis.
Mirastart builds that half. Weight-loss program pages carry no retargeting tags. Intake and inquiry forms land in infrastructure the practice owns rather than an agency inbox. Conversion events carry that a booking happened and never who booked or what for. Live-availability booking routes a weight-loss inquiry to a screening consult, instant automated reply covers the inquiry that arrives at 9pm on a Saturday, and reporting comes back in booked consults. A business associate agreement is signed where an engagement genuinely touches protected health information, and the practice stays the covered entity.
Sources
- FDA - FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs - The three claim types FDA names as false or misleading: branding implying the promoter is the compounder, describing a compounded drug as a generic version of or the same as an FDA-approved drug, and claiming it is sourced from an FDA-approved or FDA-licensed pharmacy or outsourcing facility. Also that FDA does not review compounded drugs for safety, effectiveness or quality before marketing.
- FDA - FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s (March 3, 2026) - Thirty warning letters over false or misleading claims about compounded GLP-1 products on company websites; the second set since the September 2025 letters.
- FDA - Warning Letter to GLP-1 Solution (September 9, 2025) - Website claims about compounded semaglutide and tirzepatide found false or misleading under sections 502(a) and 502(bb) of the FD&C Act, on the basis that the claims imply the products are the same as an FDA-approved product.
- FDA - Warning Letter to Altru Telehealth (June 8, 2026) - Cited only to date the enforcement as continuing into mid-2026; the letter's specific findings are not quoted here.
- FDA - Declaratory Order: Resolution of Shortages of Semaglutide Injection Products - Rests on FDA's decision memorandum dated February 21, 2025. The 503A enforcement discretion period has ended; for outsourcing facilities FDA stated it did not intend to act on shortage-list-dependent conditions until May 22, 2025.
- FDA - Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products - The tirzepatide injection shortage determination, dated December 2024.
- FDA - FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize - FDA's own statement of the compounding position after the shortages resolved, including that semaglutide and tirzepatide do not appear on the drug shortage list.
- FDA - FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (April 30, 2026) - FDA did not identify sufficient evidence of clinical need for outsourcing facilities to compound the three from bulk substances. Comments were invited through June 29, 2026; this is a proposal, and no final determination was found as of September 2026.
- FTC - Health Products Compliance Guidance - Substantiation required before dissemination for all objective product claims; competent and reliable scientific evidence, generally randomized controlled human clinical testing, for health benefits; testimonials are not substitution; a "Results not typical" disclaimer does not cure a dramatic testimonial. Issued December 2022, written around supplements, foods, drugs and devices; it does not name med spas or injectables. Business guidance, not law.
- Meta - Drugs and Pharmaceuticals (Advertising Standards, Restricted Goods and Services) - LegitScript certification or Meta internal review, Meta authorization, 18 and over targeting and eligible countries to promote prescription drugs. The advertiser types named are online pharmacies, telehealth providers and pharmaceutical manufacturers; med spas are not mentioned, so med-spa treatment is an application question.